Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment

We are grateful to Wei et al.1 for their comments on our manuscript reporting the European Society for Medical Oncology (ESMO) Expert Consensus Statements (ECS) on human epidermal growth factor receptor 2 (HER2)-low breast cancer.2 The authors argue that, based on the inclusion criteria of the ASCENT3 and DESTINY-Breast044 phase III trials, trastuzumab deruxtecan (T-DXd) should be prioritized over sacituzumab govitecan (SG) as second-line treatment for patients with HER2-low metastatic triple-negative breast cancer (mTNBC).